IL19 and neoplasm: First, ligand targeting using an IL-19–neutralizing antibody markedly abolished osteoclast-induced tumor proliferation in vitro, but the in vivo efficacy, and more importantly, the possible side effects of targeting stromal-derived factors are yet to be further investigated.